Sionna Therapeutics Q1 net loss $16.5M; cash $354.7M; Phase 1 dosing complete for two NBD1 stabilizers

Sionna Therapeutics, Inc.

2025-Q1 EPS reported -$620.00

Net loss of $16.5M for Q1 2025, up from $11.8M in Q1 2024; R&D expenses $13.7M vs $10.2M.
Cash and cash equivalents $354.7M as of March 31, 2025, including $199.6M net IPO proceeds; runway into 2028.
Phase 1 dosing completed for SION-719 and SION-451; topline data expected in Q2 2025.
Phase 2a POC trial and at least one dual combination MAD trial on track for H2 2025; topline data mid-2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.